GHENT, Belgium, Nov. 18, 2013 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels:ABLX] has been informed that Sofinnova Partners SAS has successfully completed a private placement of its Ablynx shares through an accelerated bookbuilding procedure.
Sofinnova has placed 3,005,406 shares at €7.26 per share (the last price on 18th November 2013 before the shares were suspended) with institutional investors in both Europe and the United States. As a result, it now has sold its complete stake in Ablynx.
Sofinnova Partners SAS is an independent venture capital firm based in Paris and has been an investor in Ablynx since 2002.
KBC Securities NV and Kempen & Co N.V. acted on behalf of Sofinnova as joint bookrunners for the placement.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 30 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
pdf version of the press release http://hugin.info/137912/R/1744039/586804.pdf
CONTACT: For more information, please contact Ablynx: Dr Edwin Moses Chief Executive Officer t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: email@example.com Marieke Vermeersch Associate Director Investor Relations t: +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e: firstname.lastname@example.org Follow us on Twitter @AblynxABLX Ablynx media relations Consilium Strategic Communications: Mary-Jane Elliott, Amber Bielecka, Lindsey Neville t: +44 207 920 2345 e: email@example.comSource:Ablynx